Cited by 184Bone health and treatmentsBone health and osteoporosis researchManagement of metastatic bone disease

The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

Open access

Henry, David, Vadhan-Raj, Saroj, Hirsh, Vera, von Moos, Roger, Hungria, Vania, Costa, Luis, Woll, Penella J, Scagliotti, Giorgio, Smith, Geoffrey, Feng, Amy, Jun, Susie, Dansey, Roger, Yeh, Howard·2014·Supportive Care in Cancer

DOI 10.1007/s00520-013-2022-1

Open this paper in CoChat — free account Open PDF

Abstract

Purpose Bone complications of metastatic disease, including skeletal-related events (SREs), impair patients' functioning and quality of life. In a randomized, phase 3 trial of 1,776 patients with metastases from solid tumors (except breast or prostate) or multiple myeloma, denosumab was non-inferior to zoledronic acid (ZA) in delaying or preventing SREs. This ad hoc analysis reports outcomes in the subgroup of 1,597 patients with solid tumors, excluding patients with multiple myeloma.Methods Patients received monthly subcutaneous denosumab 120 mg or intravenous ZA 4 mg, adjusted for creatinine clearance, with calcium and vitamin D supplementation recommended. Endpoints included times to first on-study SRE, first-and-subsequent SREs, and pain worsening.Results Denosumab significantly delayed time to first on-study SRE compared with ZA (HR, 0.81; 95 % CI, 0.68-0.96) and time to first-and-subsequent SREs (RR, 0.85; 95 % CI, 0.72-1.00). Denosumab also significantly delayed time to development of moderate or severe pain (HR, 0.81; 95 % CI, 0.66-1.00), pain worsening (HR, 0.83; 95 % CI, 0.71-0.97), and worsening pain interference in patients with no/mild baseline pain (HR, 0.77; 95 % CI, 0.61-0.96). Adverse event rates were 96 % in both groups. Grade 3 or 4 hypocalcemia, mostly without clinical sequelae, was more frequent in denosumab-treated patients (denosumab 4 %, ZA 2 %). Osteonecrosis of the jaw occurred infrequently (denosumab 0.8 %, ZA 1.1 %).Conclusions Denosumab was more effective in delaying or preventing SREs in patients with bone metastases from solid tumors and also prevented pain progression compared to ZA in this ad hoc analysis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s00520-013-2022-1

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mechanisms of Bone Metastasis
Roodman, G. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030831 · Cited by 2,752
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity
Coleman, R. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0931 · Cited by 2,489
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Fizazi, K. S., Carducci, M. A., Smith, M. R., Damião, R., Brown, J. E., Karsh, L. I., Milecki, P., Shore, N. D., Rader, M. E., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,974
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
Stopeck, A., Lipton, A., Body, J.-J., Steger, G. G., Tonkin, K. S., Boer, R. H. D., Lichinitser, M., Fujiwara, Y., Yardley, D. A., Viniegra, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7101 · Cited by 1,617
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
Henry, D. H., Costa, L., Goldwasser, F., Hirsh, V., Hungria, V., Prausová, J., Scagliotti, G. V., Sleeboom, H. P., Spencer, A. G., Vadhan‐Raj, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.3304 · Cited by 1,271
Management of cancer pain
Portenoy, R. K., & Lesage, P. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01310-0 · Cited by 1,013
Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A. R., Mackey, J. R., Apffelstaedt, J., Hussein, M. A., Coleman, R. E., Reitsma, D. J., et al. (2003) · Cancer · doi:10.1002/cncr.11701 · Cited by 872
Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, Phase III, double‐blind, placebo‐controlled trial
Rosen, L. S., Gordon, D., Tchekmedyian, N. S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., de Souza, P., Zheng, M., Urbanowitz, G., et al. (2004) · Cancer · doi:10.1002/cncr.20308 · Cited by 705
Pathologic fractures correlate with reduced survival in patients with malignant bone disease
Fred Saad, C., Lipton, A., Cook, R. J., Chen, Y., Smith, M. R., & Coleman, R. E. (2007) · Cancer · doi:10.1002/cncr.22991 · Cited by 664
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
Lipton, A., Fizazi, K. S., Stopeck, A., Henry, D. H., Brown, J. E., Yardley, D. A., Richardson, G. E., Siena, S., Maroto, P., Clemens, M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.08.002 · Cited by 592

Flagged first, then by citations

Show all 23 references

1 of the 23 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–184 of 184

A Tailored Approach for Appendicular Impending and Pathologic Fractures in Solid Cancer Metastases
do Brito, J. S., Lopes-Brás, R., Abrunhosa-Branquinho, A. N., Fernandes, I., Gomes, I., Casimiro, S., & Costa, L. (2022) · Cancers · doi:10.3390/cancers14040893 · Cited by 10
“In a post hoc analysis of a phase III trial in patients with solid tumors and multiple myeloma with bone metastases, denosumab significantly delayed the time to the first on-study SRE and the time to the first and subsequent SREs, compared to ZA [83].”
Background
Management of castrate-resistant prostate cancer in older men
Ged, Y. M. A., & Horgan, A. M. (2016) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2016.01.001 · Cited by 9
Comparative efficacy and safety of bone-modifying agents for the treatment of bone metastases in patients with advanced renal cell carcinoma: a systematic review and meta-analysis
Omae, K., Tsujimoto, Y., Honda, M., Kondo, T., Tanabe, K., Fukuhara, S., & Furukawa, T. A. (2017) · Oncotarget · doi:10.18632/oncotarget.20323 · Cited by 9
“[17], in which the dosage modification of zoledronic acid was allowed based on creatinine clearance, demonstrated a lower rate of serious AEs with denosumab (risk ratio: 0.”
BackgroundResultInfluential
The incidence and relative risk of adverse events in patients treated with bisphosphonate therapy for breast cancer: a systematic review and meta-analysis
Yang, Y., Xiang, Z.-J., Yang, J.-H., Wang, W., & Xiang, R. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919855235 · Cited by 9
Denosumab administration for bone metastases from solid tumors: a retrospective cross-sectional study
MIZUTA, K., Oshiro, H., Katsuki, R., Tsuha, Y., AOKI, Y., Tome, Y., & Nishida, K. (2023) · BMC Cancer · doi:10.1186/s12885-023-11495-w · Cited by 8
“In comparison, several studies have reported SREs occurrence rates of 11.5– 14.4% [8, 15, 16] for similar indications.”
BackgroundInfluential
Physicians’ preferences for bone metastases treatments in France, Germany and the United Kingdom
Qian, Y., Arellano, J., Gatta, F., Hechmati, G., Hauber, B., Mohamed, A. F., Bahl, A. K., von Moos, R., & Body, J. (2018) · BMC Health Services Research · doi:10.1186/s12913-018-3272-x · Cited by 8
Correlations between Immune Response and Etiopathogenic Factors of Medication-Related Osteonecrosis of the Jaw in Cancer Patients Treated with Zoledronic Acid
Ciobanu, G. A., Mogoantă, L., Popescu, S. M., Ionescu, M., Munteanu, C. M., Staicu, I. E., Mercuţ, R., Georgescu, C. C., Scrieciu, M., Vlad, D., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814345 · Cited by 7
The Totality of Evidence for SDZ-deno: A Biosimilar to Reference Denosumab
Vogg, B., Poetzl, J., Schwebig, A., Sekhar, S., Kivitz, A., Krivtsova, N., Renner, O., Body, J.-J., & Eastell, R. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.08.007 · Cited by 8
Bone Metastasis: Molecular Mechanisms, Clinical Management, and Therapeutic Targets
Wen, J., Li, B., Wang, S., Yao, Y., Huang, Z., & Yu, D. (2026) · MedComm · doi:10.1002/mco2.70604 · Cited by 11
“Although the effects of zoledronate and denosumab were not significantly different in terms of disease progression or OS in patients with BRCA, denosumab was more effective in delaying or preventing SREs (NCT00321464, NCT00330759) [ 267, 268 ].”
Prevalence of Precursory Signs of Atypical Femoral Fractures in Patients Receiving Bone‐Modifying Agents for Bone Metastases: A Cross‐Sectional Study
Kaku, T., Oh, Y., Sato, S., Koyanagi, H., Funauchi, Y., Hirai, T., Yuasa, M., Matsukura, Y., Yoshii, T., Nakagawa, T., et al. (2023) · JBMR Plus · doi:10.1002/jbm4.10749 · Cited by 7
Effects of zoledronic acid and ibandronate in the treatment of cancer pain in rats with lung cancer combined with bone metastases
Wang, G., Chen, J., Ma, R., Xu, W., Yan, C., & Niu, C. (2018) · Oncology Letters · doi:10.3892/ol.2018.8804 · Cited by 7
A Comparison of the Efficacy and Safety of Denosumab and Zoledronic Acid in Patients with Bone Metastatic Breast Cancer Receiving CDK4/6 Inhibitor Therapy
Öner, İ., Anık, H., İnci, B. K., Tolunay, P. K., Ateş, Ö., Arslan, Ü. Y., & Karaçin, C. (2025) · Medicina · doi:10.3390/medicina61020360 · Cited by 6
“Frequently reported adverse effects in both treatment groups aligned with those commonly reported in the literature [22,34,39].”
Disease-specific Mortality of Differentiated Thyroid Cancer With Distant Metastases
Howaidi, A., Alswailem, A. A., Hakami, A., Hadadi, A., Alturki, D., Abothenain, F., Alobaid, L. A., Ewain, N. S., Murugan, A. K., & Alzahrani, A. S. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf034 · Cited by 6
“Antiresorptive drugs such as bisphosphonate and denosumab might have an antineoplastic and antiresorptive effect by working on the tumor microenvir-onment [39].”
Therapeutic options for different metastatic sites arising from renal cell carcinoma: A review
Wang, X., Lin, Q., Qian, Z., Wu, Q., Cheng, D., Wei, J., Song, L., Huang, S., Chen, X., Wang, P., et al. (2024) · Medicine · doi:10.1097/md.0000000000038268 · Cited by 6
“[97] An analysis by CARSTEN NIEDER et al demonstrated that the patients with BOM-RCC undergoing treatment with cabozantinib exhibited significantly improved prognoses compared to those receiving everolimus.”
Result
Managing Intraoral Lesions in Oral Cancer Patients in a General Dental Practice: An Overview
Kim, R. H.-K., Yang, P. G., & SUNG, E. C. (2016) · Journal of the California Dental Association · doi:10.1080/19424396.2016.12220974 · Cited by 6
Osteonecrosis of the jaw (ONJ) in renal cell cancer patients after treatment including zoledronic acid or denosumab
Fusco, V., Bedogni, A., & Campisi, G. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2159-6 · Cited by 6
“published by Supportive Care in Cancer comparing efficacy of denosumab versus zoledronic acid in patients with bone metastases of advanced solid tumours [1] comes to integrate the original reports of three pivotal large randomized phase 3 trials [2–4], the publication by Saad et al.”
BackgroundResultInfluential
Medication-Related Osteonecrosis of the Jaw: An Evidence-Based 2025 Position Statement from a Korean Multidisciplinary Task Force
Kim, J., Kong, S. H., Kim, J., Kwak, M. K., Kim, J., Oh, J.-H., Park, H., Kim, B., Lee, Y., Han, J. J., et al. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2025.2712 · Cited by 5
Bone-modifying agents for non–small-cell lung cancer patients with bone metastases during the era of immune checkpoint inhibitors: A narrative review
Kim, J., Jeong, C., Lee, J., Ha, J., Baek, K., Kim, S., An, T. J., Park, C. K., Yoon, H. K., & Lim, J. U. (2023) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.09.002 · Cited by 5
Promising Targets and Current Clinical Trials in Metastatic Squamous Cell Lung Cancer
Vincent, M. D. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00320 · Cited by 6
“035), and also which was associated with a lower incidence of SREs than zoledronic acid (53).”
Background
Efficacy and safety of denosumab versus zoledronic acid in delaying skeletal-related events in patients with gastrointestinal cancer, pancreas-biliary system cancer, and other rare cancers
Imai, H., Saijo, K., Yamada, H., Ouchi, K., Okada, Y., Komine, K., Takahashi, M., Takahashi, S. I., Takahashi, M., Shimodaira, H., et al. (2016) · Journal of bone oncology · doi:10.1016/j.jbo.2016.10.002 · Cited by 5
[Progress on medication-related osteonecrosis of the jaw].
Wang, Q., Liu, J.-Y., & Pan, J. (2018) · PubMed Central · doi:10.7518/hxkq.2018.05.019 · Cited by 4
Definition, Clinical Features and Staging of Medication-Related Osteonecrosis of the Jaw
Otto, S., Kwon, T., & Assaf, A. T. (2014) · Springer eBooks · doi:10.1007/978-3-662-43733-9_4 · Cited by 4
High Fracture Risk of Femoral Bone Metastasis Treated with Palliative Radiotherapy in Recent Years
Makita, K., Hojo, H., Oyoshi, H., Fujisawa, T., Nakamura, M., Uchida, G., Koike, Y., Zhou, Y., Tomizawa, K., Fukushi, K., et al. (2024) · Current Oncology · doi:10.3390/curroncol31120549 · Cited by 3
Transient increase in skeletal-related events after discontinuation of high-dose denosumab in cancer patients
Setsu, N., Yokoyama, N., Esaki, T., Yamaguchi, M., Tokunaga, E., & Negishi, T. (2025) · Journal of bone oncology · doi:10.1016/j.jbo.2025.100717 · Cited by 3
“High-dose denosumab has been reported to provide modestly better prevention of SREs compared with zoledronic acid [3,7,8], as well as improved pain control [9,10].”
Dual role of autophagy in bone metastasis: mechanistic insights and therapeutic targeting
Gu, X. (2025) · American Journal of Clinical and Experimental Urology · doi:10.62347/qcpv6064 · Cited by 3
Non-Radiation Based Early Pain Relief Treatment Options for Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: A Systematic Review
Brouns, A., Bie, B. D., Everdingen, M. H. J. V. D. B.-V., Dingemans, A. C., & Hendriks, L. E. L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.509297 · Cited by 3
Combining immune checkpoint inhibitors with denosumab: a new era in repurposing denosumab in oncology?
Deligiorgi, M. V., Panayiotidis, M. I., & Trafalis, D. T. (2020) · PubMed · Cited by 3
Repurposing denosumab in breast cancer beyond prevention of skeletal related events: Could nonclinical data be translated into clinical practice?
Deligiorgi, M. V., Panayiotidis, M. I., & Trafalis, D. T. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1839416 · Cited by 3
“Contrary to clinical trials showing absence of AFFs in patients receiving denosumab for treatment of bone metastatic disease [90], a retrospective review showed an incidence of clinical AFFs of 0.”
Result
Systematic Review-Based Treatment Algorithm for the Multidisciplinary Treatment of Lung Cancer Bone Metastases
Lim, A. R., Yoon, W. S., Park, S., & Rim, C. H. (2024) · Cancers · doi:10.3390/cancers16244144 · Cited by 2
Management of upper extremity bone metastases
Riediger, M., Evaniew, N., & Ghert, M. A. (2014) · Current Orthopaedic Practice · doi:10.1097/bco.0000000000000177 · Cited by 2
Management of Locally Advanced and Metastatic Pheochromocytoma and Paraganglioma
Román-Gonzaléz, A., Vásquez, P. J., Hyde, S. M., Jessop, A., & Jiménez, C. (2016) · Springer eBooks · doi:10.1007/978-3-319-44136-8_15 · Cited by 2
Medication-Related Osteonecrosis of the Jaw: An Overview
Blašković, M., & Blašković, D. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.86241 · Cited by 2
The burden of skeletal-related events in four Latin American countries: Argentina, Brazil, Colombia, and Mexico
Perlaza, J. G., Aziziyeh, R., Zhou, A., Barbosa, V. D. S., Amaya, J., Caporale, J., Alva, M. E., Forero, J., Tanaka, S., Suri, G., et al. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.1962664 · Cited by 2
“Vertebral fracture 27,061,296 (100) 140,855,041 (100) 37,223,768 (100) 31,318,732 (100) 236,458,837 (100) Prostate cancer 3,487,435 (13) 22,237,947 (16) 5,865,856 (16) 4,909,724 (16) 36,500,962 (15) Breast cancer 7,783,294 (29) 32,709,078 (23) 8,005,311 (22) 7,852,960 (25) 56,350,643 (24) Other ST 12,899,043 (48) 62,6…”
Efficacy and safety of bone management agents administered at 12 weeks vs. 4 weeks in patients with bone metastases: A systematic review
Sato, J., Kodaira, M., Harada, H., Iguchi, H., Yoshida, T., Shibata, H., & Diagnosis and treatment of bone metastasis: comprehensive guideline (the 2nd Edition) developing group (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231203720 · Cited by 2
Combining a 9-month tailored physical exercise program with osimertinib and denosumab in a patient affected by advanced NSCLC with multiple osteolytic bone lesions: A case report
Borsati, A., Ciurnelli, C., Belluomini, L., Sposito, M., Insolda, J., Toniolo, L., Trestini, I., Tregnago, D., Milella, M., Schena, F. F., et al. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e42768 · Cited by 2
Managing Bone Metastases with Denosumab: Real-World Data and Critical Monitoring Points in Breast, Lung, and Prostate Cancers
Orhan, S. O., Orhan, B., ESENBUĞA, Ş., Sali, S., Caner, B., Ocak, B., Şahin, A. B., Deligönül, A., Evrensel, T., & Çubukçu, E. (2025) · Medicina · doi:10.3390/medicina61091637 · Cited by 2
Case series: Osteonecrosis of the jaw related to denosumab preceded by bisphosphonates in cancer and osteoporotic patients
Falinda, D., & Malden, N. (2022) · Advances in Oral and Maxillofacial Surgery · doi:10.1016/j.adoms.2022.100258 · Cited by 2
Lack of evidence regarding bone metastases of genitourinary cancers: interventions by surgery, radiotherapy, and bone-targeted systemic therapy
Miyake, M., Owari, T., & Fujimoto, K. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.04.52 · Cited by 2
Osteonecrosis of the Jaw in Association with Targeted Therapy
Troeltzsch, M., Troeltzsch, M., Pache, C., & Woodlock, T. (2014) · Springer eBooks · doi:10.1007/978-3-662-43733-9_18 · Cited by 1
Impacto econômico da adoção de denosumabe em pacientes com metástases ósseas ou mieloma múltiplo sob a perspectiva do sistema de saúde privado brasileiro
Tanaka, S., Suri, G., Arancibia, A., Nascimento, D., Magliano, C. A. D. S., & Aratangy, G. (2020) · Jornal Brasileiro de Economia da Saúde · doi:10.21115/jbes.v12.n1.p16-22 · Cited by 1
Bone metabolism and the development of denosumab: a narrative review
Niu, X.-H., & Xu, H. (2021) · Translational Breast Cancer Research · doi:10.21037/tbcr-20-69 · Cited by 1
Efficacy and Safety of Denosumab Versus Zoledronic acid in Suppressing Bone Metastases of Breast Cancer
Gabr, A., Badawy, S. A., Abdalla, A. Z., Zaki, E. M., & Mohammed, A. H. (2022) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2022.223620 · Cited by 1
“(20) concluded that denosumab was significantly superior to ZA in delaying time to first-and-subsequent SREs.”
Background
Investigation of Prescription Status and Exploration of Risk Factors Related to Denosumab-Induced Hypocalcemia in Combination Therapy with 1α,25-Dihydroxy-vitamin D3
Ikegami, K., Saito, M., Imai, S., Kizaki, H., Yasumuro, O., Funakoshi, R., & Hori, S. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b22-00649 · Cited by 1
Comparative efficacy of bone-modifying agents in the treatment of lung cancer bone metastases: immunotherapy era
Sun, D., Zhu, H., Xu, Q., Wang, Y., Peng, Y., Tian, Y., Yu, J., & Wang, Z. (2025) · Future Oncology · doi:10.1080/14796694.2025.2525744 · Cited by 1
Therapie von Knochenmetastasen
Link, H. (2014) · Der Onkologe · doi:10.1007/s00761-014-2671-9 · Cited by 1
Métastases osseuses des cancers bronchopulmonaires
Jacoulet, P. (2015) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(16)30028-3 · Cited by 1
Bisphosphonates, Denosumab, and Anabolic Agents in the Treatment of Metastatic Bone Disease
Olgun, Z. D., Gianakos, A. L., Jo, J. E., & Lane, J. M. (2015) · Springer eBooks · doi:10.1007/978-1-4614-5662-9_12 · Cited by 1
“In most comparisons it appears to be more effective than bisphosphonates with the exception of multiple myeloma [ 16 – 22 ].”
Background
Impact of Monthly 120 Mg Denosumab on Bone Metabolism in Bone-metastatic Prostate Cancer Undergoing Androgen Deprivation Therapy
Miyakawa, J., Taguchi, S., Suzuki, M., Endo, K., Nose, Y., Sato, T., Ishikawa, A., Fukuhara, H., & Homma, Y. (2017) · Asian Pacific Journal of Cancer Care · doi:10.31557/apjcc.2017.2.3.41-46 · Cited by 1
Análisis del impacto presupuestario de denosumab para la prevención de eventos relacionados con el esqueleto en adultos con metástasis óseas de tumores sólidos en España
Seguí, M. Á., Durán, I., Roldán, C., Oyagüez, I., Casado, M. Á., Gutiérrez, L. D. C. M., Gasquet, J. A., & Isla, D. (2014) · PharmacoEconomics Spanish Research Articles · doi:10.1007/s40277-014-0039-6
Längerer Schutz vor Skelettkomplikationen
Klein, F. (2014) · Im Focus Onkologie · doi:10.1007/s15015-014-1291-y
Bone Target Therapy in Urologic Malignancies
Bier, S., Todenhöfer, T., & Stenzl, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-42603-7_51-1
WITHDRAWN: Osteonecrosis of the jaw in patients treated by denosumab for malignant bone disease: descriptive study on 9 cases.
Lan, R., Saïd, M. H., Foletti, J. M., Massereau, E., & Chossegros, C. (2018) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2018.04.004
Role of Chemotherapy in Cancer Pain Management
Lokeshwar, N., Bakshi, A. V., & Pareek, V. (2018) · Jaypee Brothers Medical Publishers (P) Ltd. eBooks · doi:10.5005/jp/books/13057_53
Controversies in the Management of Solid Tumor Bone Metastases
FARACH, A. M., Butler, E. B., & Teh, B. S. (2019) · Medical radiology · doi:10.1007/174_2019_217
How Is Receptor Activator of Nuclear Factor-κβ/Receptor Activator of Nuclear Factor-κβ Ligand Targeting Ranked as an Immuno-Oncology Target for NSCLC: a Pathway Unclear as yet?
Chu, Q. S.-C. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.07.011
Análise econômica do denosumabe e dos bisfosfonatos no tratamento de pacientes com metástase óssea
Matuoka, J. Y. (2019) · doi:10.11606/t.7.2019.tde-23022021-095026
Intraosseous Squamous Cell Carcinoma Associated with Denosumab-Induced Osteonecrosis of the Jaw
Martínez, S. B., Cuéllar, C. N., Vila, C. N., Weiss, E. P., Romanya, R. P., de Velasco, Á. D. A. F., Escrig, M., de Vera, J. L. D. C. P., Pérez, I. R., Sánchez‐Pérez, A., et al. (2021) · Applied Sciences · doi:10.3390/app11167646
“[15], in which the incidence of MRONJ was low, similar in both treatment groups (denosumab and zolendronic acid), and mostly associated with risk factors.”
Result
Cost-effectiveness of denosumab in preventing skeletal-related events in bone metastases
Giuliani, J. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211038002
Drug therapy for bone metastasis of malignant tumor: theory, progress, and potential.
Tian, J.-Z., Ma, N.-N., Li, X., Shang, K., & Cao, B.-W. (2022) · Neoplasma (Bratislava) · doi:10.4149/neo_2021_211006n1412
Bone Target Therapy in Urologic Malignancies
Bier, S., Todenhöfer, T., & Stenzl, A. (2019) · Springer eBooks · doi:10.1007/978-3-319-42623-5_51
Systemic Therapy
Marmé, F. (2016) · Springer eBooks · doi:10.1007/978-3-319-46356-8_20
Prostate Cancer
Nelson, W. G., Haffner, M. C., & Yegnasubramanian, S. (2015) · Wiley eBooks · doi:10.1002/9781118468678.ch28
Endokrines System und Immunmodulation
(2018) · Elsevier eBooks · doi:10.1016/b978-3-437-23672-3.00008-1
Endokrines System und Immunmodulation
(2015) · Elsevier eBooks · doi:10.1016/b978-3-437-23671-6.00008-0
Efficacy and Safety of Bone Management Agents Administered at 12 Weeks vs. 4 Weeks in Patients with Bone Metastases: A Systematic ReviewPreprint
Sato, J., Kodaira, M., Harada, H., Iguchi, H., Yoshida, T., & Shibata, H. (2022) · Research Square · doi:10.21203/rs.3.rs-1790327/v1
Skeletal Complications
Via, M. A., Iofin, I., Liu, J., & Mechanick, J. I. (2022) · Holland‐Frei Cancer Medicine · doi:10.1002/9781119000822.hfcm129.pub2
Бессимптомные метастазы в кости при раке молочной железы. «Лечить нельзя наблюдать» — где можно поставить запятую?
Багрова, С. Г. (2022) · Malignant tumours · doi:10.18027/2224-5057-2022-12-3s1-39-42
Brust- und gynäkologische Tumoren – medikamentöse Therapie ossärer Metastasen
Sommer, K., Wulf, S., & Gallwas, J. K. S. (2023) · Frauenheilkunde up2date · doi:10.1055/a-1931-5820
Economic evaluation of denosumab in patients with solid tumors with bone metastasis at the IMSS
Carlos‐Rivera, F., Guzmán-Caniupan, J. A., Hernández-Garduño, A. G., Alva-Esqueda, M., Maraumont, T. A.-D., & Camacho-Cordero, L. M. (2023) · Gaceta Mexicana de Oncología · doi:10.24875/j.gamo.m23000241
Rhumatismes inflammatoires liés aux immunothérapies et prise en charge des métastases osseuses
Chevet, B. (2023) · Revue du Rhumatisme · doi:10.1016/s1169-8330(23)00150-3
Models of multidisciplinary management
Tsao, M. N., Barnes, E. A., & Chow, E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87688-9.00014-3
Additional file 1 of Denosumab administration for bone metastases from solid tumors: a retrospective cross-sectional study
MIZUTA, K., Oshiro, H., Katsuki, R., Tsuha, Y., Aoki, Y., Tome, Y., & Nishida, K. (2023) · Figshare · doi:10.6084/m9.figshare.24355040
Determinants of outcome in cancer patients with medication-related osteonecrosis of the jaw: A 19-year retrospective study
Ward, J., Singh, A., White, C., Riedel, E., Lewis, R., Yom, S. K., Halpern, J. L., Randazzo, J. D., Kronstadt, K. L., Huryn, J. M., et al. (2024) · Oral Oncology Reports · doi:10.1016/j.oor.2024.100488
“Henry et al. found that for cancer patients treated with zoledronic acid or denosumab, there was a 0.5 % chance of developing MRONJ after 1 year, a 1.3 % chance after 2 years and a 1.8 % chance after 3 years [25].”
BackgroundInfluential
Bisphosphonates, Denosumab, and Anabolic Agents in the Treatment of Metastatic Bone Disease
Jawad, M. U., & Randall, R. L. (2024) · Springer eBooks · doi:10.1007/978-3-031-52001-3_13
Bone-modifying agents for bone metastasis in patients with breast cancer
Park, L. C., & Lee, E. (2024) · Kosin Medical Journal · doi:10.7180/kmj.24.121
“Several randomized phase 3 clinical trials demonstrated denosumab was more effective than zoledronic acid in SRE prevention and pain reduction [19-22].”
Background
Routine use of denosumab for prevention of skeletal-related events in patients with bone metastases from prostate carcinoma in Bulgaria: a prospective observational study
Tomova, A., Ianakieva, V., Björklöf, K., Olszewski, A., & Petrova, M. Y. (2024) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2024.2366490
“Its superiority versus zoledronic acid in delaying the time to first SRE has been demonstrated in patients with castration-resistant prostate cancer (CRPC), breast cancer and other solid tumors in three large, randomized clinical trials [7, 12– 14].”
Hot issues on Chinese expert consensus of prostate cancer management
Han, S., Sheng, X., Qin, X., Wu, P., Yang, Z., Zeng, H., Liu, H., Wang, B., Zhou, Z., Song, G., et al. (2024) · UroPrecision · doi:10.1002/uro2.76
A real-world study of denosumab-related hypocalcaemia based on the US food and Drug Administration Adverse Event Reporting System databasePreprint
Zhang, N., Fang, X., Lin, Y., Li, Q., & Zhang, W. (2024) · Research Square · doi:10.21203/rs.3.rs-5283355/v1
Osteonecrosis of the jaw: Prevention and management
Gkastaris, K., & Anastasilakis, A. D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00161-8
Retrospective Analysis of Osteonecrosis of the Jaw in Breast Cancer Patients Receiving Bone Modifying Agents for Bone MetastasesPreprint
Praska, T., Griswold, C. R., Noyes, M., Mina, L. A., McGary, A. K., Yu, C., & Raheem, F. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5068799
Cardiovascular effects of bone-active medications across the clinical spectrum
Rodríguez, A. J., & Ebeling, P. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00160-6
Comparison of Hounsfield Units and Vertebral Bone Quality Score for the Prediction of Time to Pathologic Fracture in Mobile Spine Metastases Treated With Radiotherapy
Chu, P.-J., Yen, H., Huang, P., & Hu, M. (2025) · Global Spine Journal · doi:10.1177/21925682251325173
“4,5 Clarifying whether an-tiresorptive agents were more commonly prescribed for these speci ﬁ c cancers could provide deeper insights into the study ’ s ﬁ ndings and account for potential confounders, such as whether the presence of a higher proportion of lung cancer patients in speci ﬁ c subgroups…”
Supportive Parenteral Agents
Parkes, J., & Moreira, F. (2026) · Advances in computational intelligence and robotics book series · doi:10.4018/979-8-3373-6551-0.ch014
Pharma Update Mammakarzinom
Thomssen, C. (2014) · Der Gynäkologe · doi:10.1007/s00129-013-3285-9

Authors: Henry, D., Vadhan-Raj, S., Hirsh, V., von Moos, R., Hungria, V., Costa, L., Woll, P. J., Scagliotti, G., Smith, G., Feng, A., Jun, S., Dansey, R., & Yeh, H.
Affiliations: Pennsylvania Hospital (US)
McGill University Health Centre (CA)
University of Sheffield (GB)
University of Turin (IT)
Amgen (United States) (US)
Corresponding author: Henry, David
ORCID: Henry, David
Woll, Penella J
Scagliotti, Giorgio
Venue: Supportive Care in Cancer
Publisher: Springer Science and Business Media LLC
Published: 2013-10-26
Volume: 22
Issue: 3
Pages: 679-687
ISSN: 0941-4355 (ISSN-L)
1433-7339
DOI: 10.1007/s00520-013-2022-1
OpenAlex: W2066699153
Cited by: 183
References: 23
Citations by year: 2026: 2 · 2025: 11 · 2024: 13 · 2023: 16 · 2022: 13 · 2021: 11 · 2020: 21 · 2019: 17 · 2018: 14 · 2017: 10 · 2016: 16 · 2015: 21 · 2014: 16 · 2013: 1
FWCI: 9.64
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
Locations: Supportive Care in Cancer (publishedVersion)
PubMed (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Funders: Amgen
Topics: Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Surgery › Management of metastatic bone disease
Keywords: denosumab, zoledronic acid, skeletal-related events, bone metastasis, solid tumors, bone pain, hypocalcemia, osteonecrosis of the jaw, bisphosphonates, non-inferiority, metastatic cancer
MeSH terms: Denosumab, Zoledronic Acid, Adolescent, Adult, Aged, Aged, 80 and over, Bone Neoplasms, Bone Resorption, Diphosphonates, Double-Blind Method, Female, Humans, Imidazoles, Male, Middle Aged, Multiple Myeloma, Neoplasms, Pain, Treatment Outcome, Disease Progression, Bone Density Conservation Agents, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks